Objective: To observe the effects of valsartan combined with atorvastatin on cardiac function, myocardial enzymes and thyroxine levels in patients with chronic heart failure (CHF).Methods: A total of 90 cases of CHF cases were divided into observation group and control group according to the order of single and double number, 45 cases each.In the control group, atorvastatin was given on the basis of conventional therapy, and the observation group was given valsartan on the basis of the control group.After 6 months, the differences of cardiac function indexes (LVEF, LVEDD, LVESD, E/A), myocardial enzymes (LDH, AST, CK, CK-MB) and thyroxine (TT3, TT4, FT3, FT4, TSH) in the two groups were observed.Results: After treatment, LVEF and E/A in both groups increased significantly (P<0.05);LVEDD and LVESD decreased significantly (P<0.05);LVEF 49.05%±5.37% and E/A (1.13±0.19) are higher than the control group;LVEDD (51.55±5.26) mm and LVESD (38.87±3.61) mm are lower than the control group, the difference was statistically significant (P<0.05).After treatment, two groups of LDH, AST, CK, CK-MB were significantly decreased (P<0.05), LDH, AST, CK and CK-MB in the observation group were (165.06+29.45) IU/L, (31.51+13.33) IU/L, (96.45+29.58) mmol/L and (19.53+8.75) mmol/L, respectively, lower than the control group, the differences were statistically significant (P<0.05).After treatment, two groups of TT3 and FT3 increased significantly (P<0.05) while TT4, FT4 and TSH levels had no significant changes (P>0.05), the observation group TT3 and FT3 were (1.37+0.33) mol/L and (2.61+0.69) pmol/L, respectively, significantly higher than the control group (P<0.05).Conclusions: Valsartan combined with atorvastatin in the treatment of CHF, can improve cardiac function and myocardial protection effect, and can effectively promote the recovery of thyroid hormone levels, better than the single use of atorvastatin.%目的:观察缬沙坦联合阿托伐他汀对慢性心力衰竭(CHF)患者心功能、心肌酶谱及甲状腺素水平的影响.方法:90例CHF病例依据纳入顺序单双号为观察组和对照组,各45例.对照组在常规治疗的基础上给予阿托伐他汀,观察组在对照组的基础上给予缬沙坦.治疗6个月,观察两组心功能指标(LVEF、LVEDD、LVESD 、E/A)、心肌酶谱(LDH、AST、CK、CK-MB)及甲状腺素水平(TT3、TT4、FT3、FT4、TSH)的差异.结果:治疗后,两组LVEF、E/A明显上升(P<0.05)而LVEDD、LVESD明显下降(P<0.05),且观察组LVEF、E/A高于对照组而LVEDD、LVESD低于对照组,差异有统计学意义(P<0.05);治疗后,两组LDH、AST、CK、CK-MB水平均明显下降(P<0.05),观察组LDH、AST、CK、CK-MB均低于对照组,差异均有统计学意义(P<0.05);治疗后,两组TT3、FT3明显上升(P<0.05)而TT4、FT4、TSH水平无明显变化(P>0.05),观察组TT3、FT3均高于对照组,差异有统计学意义(P<0.05).结论:缬沙坦联合阿托伐他汀治疗CHF时改善心功能、保护心肌作用确切,并能有效促进甲状腺素水平恢复,优于单用阿托伐他汀.
展开▼
